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Background: Despite strong recommendations for colorectal cancer (CRC) screening, participation rates are low.
Understanding factors that affect screening choices is essential to developing future screening strategies. Therefore,
this study assessed patient willingness to use non-invasive stool or blood based screening tests after refusing
colonoscopy.
Methods: Participants were recruited during regular consultations. Demographic, health, psychological and
socioeconomic factors were recorded. All subjects were advised to undergo screening by colonoscopy. Subjects
who refused colonoscopy were offered a choice of non-invasive tests. Subjects who selected stool testing received
a collection kit and instructions; subjects who selected plasma testing had a blood draw during the office visit. Stool
samples were tested with the Hb/Hp Complex Elisa test, and blood samples were tested with the Epi proColon® 2.0
test. Patients who were positive for either were advised to have a diagnostic colonoscopy.
Results: 63 of 172 subjects were compliant to screening colonoscopy (37%). 106 of the 109 subjects who refused
colonoscopy accepted an alternative non-invasive method (97%). 90 selected the Septin9 blood test (83%), 16
selected a stool test (15%) and 3 refused any test (3%). Reasons for blood test preference included convenience of
an office draw, overall convenience and less time consuming procedure.
Conclusions: 97% of subjects refusing colonoscopy accepted a non-invasive screening test of which 83% chose
the Septin9 blood test. The observation that participation can be increased by offering non-invasive tests, and that
a blood test is the preferred option should be validated in a prospective trial in the screening setting.
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Colorectal cancer (CRC) has been estimated to afflict
1.36 million people worldwide, accounting for nearly
10% of cancers [1] and is the second most common
cause of death due to cancer in Europe [2]. It is well
established that the five-year survival rate for CRC,
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unless otherwise stated.drops to less than 5% for late stage metastatic disease. A
number of CRC screening methods aimed at early detec-
tion have been developed, and there is a substantial body
of evidence supporting the benefits of CRC screening
[3-5]. Paradoxically, despite the clear and long standing
evidence that CRC screening reduces mortality and may
reduce cancer incidence, participation rates in screening
programs remains too low, at an estimated 65% in the
US [6] and ranging from 1.9% to 54% across Europe [7].
In Germany, screening by annual guaiac fecal occult
blood tests (gFOBT) has been recommended since the
mid 1970’s, and screening by colonoscopy wastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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screening is encouraged, organized nationwide screening
activities are limited. Both methods are available without
additional cost as part of health care coverage. Estimates
of test usage in Germany indicate that for use of FOBT
within the past year, only 14% of men and 22% of
women were compliant, and that colonoscopy use within
10 years was 23% for men and 26% for women [8]
though in most instances the colonoscopy was diagnos-
tic rather than for screening. In Germany, nationwide
data on screening colonoscopy, including adenoma de-
tection, cecal intubation and complication rates amongst
others are tracked through a central registry [10]. In the
city of Berlin, the quality and performance of screening
colonoscopy has been tracked through the Berlin colon-
oscopy projects - BECOP 1&3 [9,11].
Given the low participation in CRC screening pro-
grams despite the clear medical benefit, it is important
to understand the barriers to screening to develop suc-
cessful alternative approaches. Numerous studies report
behavioral as well as structural barriers that limit screen-
ing participation. These include factors specific to the
tests themselves, such as embarrassment, fear of the pro-
cedure, or inconvenience, as well as broader factors such
as lack of access to care, limited knowledge of screening
and a lack of physician recommendation [reviewed in
12]. While these findings are clearly influenced by the
country or health system of the participants, many fac-
tors (e.g. fear) are consistently reported in different set-
tings [12]. To overcome these barriers, considerable
effort has gone in to developing educational and out-
reach programs to improve screening rates. One aspect
of this has been the demonstration that offering a choice
in tests has a positive impact on participation in screen-
ing programs [13].
As indicated above, surveys, focus groups and patient
interviews focused on understanding the resistance to
screening, demonstrate that the screening modalities
themselves (fecal sampling, bowel prep, colonoscopy
etc.) present significant hurdles to patients [12]. The
blood based test for CRC screening provides an alterna-
tive screening method based on the detection of methyl-
ated Septin9 DNA in patient plasma, and may overcome
these barriers [14]. The test uses a standard EDTA
plasma sample collected at the physician’s office or diag-
nostic laboratory.
The performance characteristics of the Epi proColon
2.0 CE blood test have been reported to be in the range
of 70% sensitivity and 90% specificity in a number of
studies [14-17]. The test has no dietary or time restric-
tions. The objective of the current study was to deter-
mine the impact of offering a new blood based test on
the participation rate for CRC screening in Berlin,
Germany rather than on characterizing performance.In addition, the study aimed to determine the relation-
ships between demographic variables and test choice,
and to survey the reasons for choosing non-invasive
tests.Methods
The study protocol was reviewed and approved by the
Institutional Review Board of the Charite hospital. Sub-
jects were recruited at 15 sites in Berlin (Germany) and
surrounding areas, all of which were managed under the
Charite hospital review board. All subjects provided
written informed consent. Inclusion criteria were: age 50
to 75; Patient showing no symptoms that may indicate a
tumor of the colon; Patient has no known inflammatory
bowel disease; Patient has no known familial predispos-
ition for colorectal cancer; Patient has no known strong
family history or genetic predisposition to colorectal
cancer; Informed Consent provided. The study design is
summarized in Figure 1.Study subjects
Subjects were recruited during regular consultations
with primary care physicians or company doctors as out-
lined in the Additional file 1. Physicians followed a stan-
dardized recommendation script, first offering screening
by colonoscopy, and for patients who refused, offered
the option of non-invasive testing with the stool based
immunochemical fecal occult blood test (FIT) or the
Septin9 blood test. Although the protocol stated that all
patients fitting the inclusion criteria be asked to partici-
pate, the total number of potential patients who could
be invited to be screened was not recorded. 174 CRC
screening eligible subjects were enrolled and provided
demographic, health, psychological and socioeconomic
data by a questionnaire (Tables 1, 2 and 3). Two subjects
who were younger than 50 were removed from the ana-
lysis. Although the recommended age for screening by
colonoscopy is 55 in Germany, screening by FIT/FOBT
is promoted for patients aged 50+ and therefore all sub-
jects age 50+ were included in the analysis. All subjects
were advised to undergo screening by colonoscopy and
the screening decision was recorded. Subjects who ac-
cepted colonoscopy were not included in the remainder
of the study.
Subjects who refused screening colonoscopy were of-
fered the option of either a FIT test (Hb / Hp–Complex
ELISA, MDI Laboratorien GmbH, Berlin Germany) or
an Epi proColon blood test (Epigenomics AG, Berlin,
Germany). Physicians provided approved descriptive ma-
terials for each test. These subjects also filled out an
additional questionnaire focused on determining the
basis for their screening decisions (Additional file 1:
Table S1–S11).
Figure 1 Flow chart outline of the study design. The number of subjects enrolled, the number refusing colonoscopy, and the number choosing a
blood test, stool test, or refusing any test are indicated.
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Subjects who selected a stool test were provided the
Hb/Hp–Complex ELISA stool collection kit, instructions
for sample collection, and were requested to provide the
fecal sample to the testing lab. Subjects who selected the
plasma test provided a blood sample as part of the phys-
ician visit. For both methods, tests were performed fol-
lowing the manufacturers instruction at a qualified
laboratory and the test results were recorded. Individuals
who were positive for either test were recommended to
have a diagnostic colonoscopy.
Statistical analysis
Answers from the questionnaires were reported as sim-
ple numbers and percentages. The significance of demo-
graphic, health, psychological and medical variables
between colonoscopy acceptors and refusers were ana-
lysed by the Chi squared test, (p < 0.05). To correct forage, logisitic regression models were used with acceptor/
refuser as response and age as an additional variable.
Results
Of the 174 subjects enrolled, 2 were under the age of 50
and were excluded. Sixty three (36.6%) opted for screen-
ing colonoscopy and 109 (63.4%) refused (Figure 1).
Demographic data for the 172 included subjects is sum-
marized in Table 1 and the number refusing colonoscopy
is indicated.
Self reported health information is reported in Table 2,
and knowledge of cancer, colorectal cancer and general
gastrointestinal health is outlined in Table 3, and the
numbers refusing colonoscopy are indicated. For a
number of parameters, a more detailed breakdown is
reported in the Additional file 1: Table S1. Subject vari-
ables were analyzed using the Chi squared test to deter-
mine differences between colonoscopy acceptors and
Table 1 Demographic information of all subjects enrolled
in the study
Total Refused colonoscopy
N % 95% CI*
Enrolled 172 109 63.4
Gender
Female 104 69 66.3 56.8–74.7
Male 67 40 59.7 47.7–70.6
Age
50–60 70 44 62.9 51.1–73.2
60–69 65 45 69.2 57.2–79.1
70+ 33 17 51.5 35.2–67.5
Ethnicity
German 137 89 65.0 56.7–72.4
Not German 35 20 57.1 40.9–72.0
Education
None / Basic 69 43 62.3 50.5–72.8
A level / University 82 48 58.5 47.7–68.6
Proffession/Work
Employed 88 55 62.5 52.1–71.9
Retired 71 43 60.6 48.9–71.1
Unemployed 7 6 85.7 48.7–99.3
Monthly income
≤1000 € 36 29 80.6 65.0–90.2
1001–2000 € 75 43 57.3 46.1–67.9
>2000 € 30 19 63.3 45.5–78.1
No Data 31 18 58.1 40.8–73.6
Health insurance
State 158 101 63.9 56.2–71.0
Private 12 8 66.7 39.1–86.2
No data 2 0 0
*Confidence Interval.
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amount of weekly exercise (p ≤ 0.001) where those who
excercised more frequently were also more likely to opt
for a non-invasive test than a colonoscopy (Table 4). In
the analysis with additional subgroups, subjects per-
ceived CRC risk (p ≤ 0.01) was also significant, while fac-
tors such as monthly income and education level were
close to significant (Table 4). While these variables were
significant, no trend was observed for these variables.
When further analyzed using logistic regression models
with age as an additional variable, only level of exercise
remained significant (p < 0.01). The remaining variables
did not differ significantly at the p ≤ 0.05 level. General
awareness of screening methods and prior use of tests is
presented in Table 5, which illustrates that 95% ofparticipants had an awareness of colorectal cancer
screening tests.
The subjects who refused colonoscopy were offered
non-invasive screening. Of the 109 subjects who rejected
colonoscopy, 90 (82.6%) opted for the blood test, 16
(14.7%) opted for the Hb/Hp–Complex ELISA FOBT
test, and 3 (2.8%) refused both options (Figure 1). These
subjects also answered questions related to their screen-
ing decision. As indicated in the Additional file 1: Table
S2, the top three reasons for rejecting colonoscopy were
being uncomfortable with the bowel preparation for col-
onoscopy (54%), fear of colorectal cancer itself (44%)
and fear that colonoscopy would be painful (32%). These
results were corroborated in a follow-up question asking
what would convince subjects to be screened by colon-
oscopy where 38% indicated an improved bowel prepar-
ation, 29% indicated cancer prevention by polypectomy
and 24% indicated that overcoming fears would change
their minds (Additional file 1: Tables S3). In addition,
when asked why they chose one of the screening tests,
78% and 81% of subjects who had a blood and stool test
respectively, indicated ease of getting the test (Additional
file 1: Tables S4, S5, S7, S8). For those choosing the
blood test, primary reasons for not choosing the stool
test related to being uncomfortable with specimen hand-
ling (Additional file 1: Table S6). For those choosing the
stool test, the primary reason related to having used a
stool test in the past (Additional file 1: Table S9). As only
3 subjects rejected any form of testing, limited survey data
is available (Additional file 1: Table S10 through S12).
Finally, though not the focus of this study, the two
subjects who were positive for the Septin9 test and the
two who were positive for FIT went on to colonoscopy.
Discussion
In this observational study, we report the impact of pro-
viding a choice of non-invasive screening tests on par-
ticipation in colorectal cancer screening in Berlin,
Germany and surrounding areas. We also report the re-
sults of surveys of participants addressing their perspec-
tives on the different screening test options. In this
study, 36.6% of participants chose to have a screening
colonoscopy. Among the 63.4% who refused colonoscopy,
82.6% selected the Septin9 blood test, 14.7% selected the
stool test and 2.8% refused any test. Thus, when all
methods were considered, screening levels reached 98%
(169/172 subjects).
Study recruitment was undertaken in Occupational
Health and Primary Care settings, and therefore the fol-
lowing comparison of some of the key demographic data
(Table 1) was made with census data from the German
population [18]. The study enrolled a higher propor-
tion of women (60.8%) which may be explained in part
by the elevated ratio of women in the eligible age
Table 2 Self reported health information for all subjects enrolled in the study
Total Refused colonoscopy
N % 95% CI*
Health status
Good 130 82 63.1 54.5–70.9
Poor 41 26 63.4 48.1–76.4
Self evaluated – Risk of CRC
Small 148 97 65.5 57.6–72.7
Large 23 11 47.8 29.2–67.0
Frequency of regular exercise**
0–1 81 39 48.1 37.6–58.9
1+ 91 70 76.9 67.3–84.4
Diet
Calorie Rich, Sweets, Animal Fats and Red Meat 18 8 44.4 24.6–66.3
Fresh Fruit, Vegetables, White Meat and Fish 57 35 61.4 48.4–72.9
Varied – a bit of everything 97 66 68.0 58.2–76.5
Alcohol consumption
Up to 2–3 per week 155 98 63.2 55.4–70.4
Daily 14 8 57.1 32.6–78.6
Smoking
Non Smoking 134 85 63.4 55.0–71.1
Smoking 38 24 63.2 47.3–76.6
Number of physician visits in last year
<15 44 30 68.2 53.4–80.0
15+ 123 75 61.0 52.1–69.1
*Confidence Interval.
**Significant based on χ2 test.






Prior experience with gastro-intestinal inflammation or polyps
Yes 22 10 45.5 26.9–65.3
No 150 99 66.0 58.1–73.1
Prior Experience with any form of Cancer (excluding colorectal cancer)
Yes 13 6 46.2 23.2–70.9
No 158 102 64.6 56.8–71.6
No Data 1 1 100 5.1–100.0
Any family members with polyps
Yes 17 8 47.1 26.2–69.0
No 120 75 62.5 53.6–70.6
No Data 35 26 74.2 57.9–85.8
Any family members diagnosed with cancer
Yes 79 52 65.8 54.8–75.3
No 91 55 60.4 50.2–69.9
No Data 1 1 100.0 5.1–100.0
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Table 4 Analysis of accepting/refusing colonoscopy for
demographic parameters with detailed and collapsed
categories (χ2 – Test) and p-values of likelihood ratio test










test – p value
Gender 0.47 0.60
Age Group 0.23 1.00
Ethnicity 0.37 0.51 0.29
Education 0.07 0.76 0.08
Profession/Work 0.60 0.42 0.34
Monthly Income 0.06 0.03
Health Insurance 1.00 0.82
Health Status 0.59 1.00 0.98





Alcohol Consumption 0.48 0.87 0.47
Smoking 0.34 1.00 0.40
Number of physician














*For some demographic variables, classes were combined to increase the number
of subjects, and were analyzed (compare Table 1 and Additional file 1: Table S1).
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resentative, with lower numbers enrolled in the 70+
age group compared to the total population (20% in
the study vs 34% in the population) which reflects en-
rollment in the Occupational Health setting. Compari-
son of the migrant status of enrolled subjects was
similar to that for the Berlin region, with 20.3% not
German in the study, compared with 24% with a mi-
grant background in the population [18]. The observed
un-employment rate in the population was as expectedTable 5 Prior knowledge of CRC screening tests
Awareness of CRC Screening Tests N (%) CI
Fecal occult blood test 157 (91%) 86–95%
Colonoscopy 162 (94%) 90–97%
Sigmoidoscopy 22 (13%) 9–19%
Barium contrast enema 28 (16%) 12–23%
Septin9 blood test 36 (21%) 16–28%(4.2% in the study, 4.6% in the age matched popula-
tion) as were the rates of employed and retired sub-
jects. Finally, the distribution of education level in the
current study was higher on average than in the gen-
eral population (56% no or lower education in the
population compared with 40.4% in the study) though
using the same metric for the Berlin region, the popu-
lation estimate was 38% for no or lower education,
which compares well with the 40.4% observed in the
study [18]. While differences from the overall German
population are not unexpected, given the sample size
and the regional location of the study, the different
demographic strata are represented. They are close to
the observed levels for the Berlin region, thus allowing
for extrapolation of the results to the region, and with
caution, are also informative for the broader German
population.
Given that enrollment was in a setting where CRC
screening was promoted, this may account for the high
degree of screening knowledge observed in the study.
While the rate of acceptance of screening colonoscopy
in this study (37%) was higher than the overall reported
rate for the German population (~25%) [8], it remained
well below that reported for the US. It is unclear why
the rate of screening colonoscopy is higher than usually
observed in Germany, though it may be attributed in
part to participation in a study. As the study focused on
the screening population, subjects were asymptomatic
and representative of the broader population. It may
however, also represent an overestimate, since the num-
ber refusing enrollment was not recorded.
There are only a few reports on barriers to acceptance
of colonoscopy in the German screening population. In
a 2009 report from the Leipzig area, the primary reasons
for not being screened were a lack of awareness or rec-
ommendation for screening [19]. In a detailed survey
from the Munich area, fear of the bowel preparation,
lack of a physician recommendation and a lower interest
in screening were associated with avoiding colonoscopy
[20]. Interestingly, in that study, the demographics asso-
ciated with having a colonoscopy were: lower education
status, unemployment or retired, or having a primary
care physician [20].
As shown in the detailed analysis in the supplement, a
similar trend was observed for participants who com-
pleted Grade School compared with those completing A
levels, though this was reversed for those who completed
university. When these categories were aggregated, the
difference was not significant. These trends differ from
the US, where the lowest screening rates correlate with
low socioeconomic status indicators such as income,
education level and lack of work [12], and this illustrates
the importance of developing an understanding of the is-
sues at a local level. It is also interesting to note that we
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copy and other health factors such as diet, alcohol con-
sumption or smoking status.
In the current study, the primary reasons given for not
having a colonoscopy were associated with fear, discom-
fort or concern about the bowel preparation or the col-
onoscopy procedure. This outcome suggests that better
education about the procedure is a possible course for
increasing screening by colonoscopy. In addition the
primary reasons patients provided for selecting non-
invasive tests related to convenience of use, and the se-
lection of a blood test over a stool test was based on a
preference not to handle stool samples. Thus, it appears
that the preference for the blood test is not necessarily
related to the performance of the test, but rather the
convenience it offers with blood collection available at
the physician’s office.
We observed that 97% of the participants who refused
a colonoscopy were willing to accept a non-invasive test,
despite these tests having lower performance outcomes.
This aligns with the observation that educating patients
with the evidence for the benefits of colonoscopy versus
other screening methods had no impact on their attitude
to CRC screening or their ultimate test choice [21].
Thus, understanding the patient’s motivation for screen-
ing is crucial to developing successful programs. This is
underscored in a recent trial, where offering screening
alternatives increased overall participation in a screening
program [13]. It is further illustrated by the experience
at Kaiser-Permanente in California, where, following
failed efforts to implement screening by endoscopy,
screening participation has consistently increased with
the re-introduction of a non-invasive FIT test [22], des-
pite the test having lower sensitivity.
It is clear from the results of the current study that of-
fering a blood test as part of the screening menu further
improves participation, as approximately 80 percent of
subjects opted for a blood test. It is important to note
that in the present study, the tests were provided at no
cost to participants. As the blood test is not currently
covered under national health care, the impact of cost to
patient needs further analysis. Based on the survey data,
key factors in the decision to be screened with the blood
test were trust of blood tests, being comfortable with
giving blood and the convenience of a blood draw com-
pared with providing a stool sample. It is also interesting
to note that providing test choice can improve screening
participation, similar to what was observed by Inadomi
et.al. [13] in a study in California, as well as in a discrete
choice study in the Netherlands [23].
While it is clear that the ease and convenience of a blood
test can improve screening participation, there are many
additional factors that will determine the impact of a new
screening test. In addition to performance characteristics,these include guideline recommendations, health eco-
nomic considerations, and cost to patient amongst others.
Despite this complex landscape, which includes significant
differences in philosophy and approach by region and
country, the data in this study support the idea that test
convenience is an important consideration in the success
of CRC screening programs.
With the limited sample size, and the observation of
only a small number of patients who were positive for
either non-invasive test, we did not perform statistical
analysis on the test results, or whether subjects with a
positive test result went on to colonoscopy. Anecdotally,
the two subjects who were positive for the Septin9 test
and the two who were positive for FIT went on to colon-
oscopy. Clearly, compliance with follow-up diagnostic
colonoscopy is a critical aspect in the success of a
screening program. In all four subjects, adenomas were
removed completely during colonoscopy. One patient of
the Septin9 group showed high grade intraepithelial
neoplasia and the others had low grade intraepithelial
neoplasias.Limitations of the study
The study was subject to a number of limitations. 1) It
was designed to enroll 100 subjects who refused colon-
oscopy. While this sample size was deemed sufficient to
assess general preference for the two non-invasive
screening modalities, it allows only limited observational
analysis of subgroups. 2) By protocol, the study was de-
signed to enroll all eligible subjects in each practice.
However, the study did not include a mechanism to rec-
ord the total number of subjects asked to participate or
the number who refused to participate. In this respect,
the results cannot be presented in the context of
‘intention to screen’. As a result, there may be bias in
the study, resulting in the higher than expected estima-
tion of participation rates. 3) The study was performed
in a limited geographical setting (Berlin, Germany) and
therefore, extrapolation to a broader national or broader
European context should be done with caution.Conclusions
The results of this study support the contention that pro-
viding non-invasive screening choices can augment par-
ticipation in programs for colorectal cancer screening.
The success of a screening program depends on having
tests with acceptable performance, but also on the willing-
ness of the target population to participate. This study
demonstrates that offering non-invasive test options
significantly increases compliance to colorectal cancer
screening. Furthermore the addition of a convenient blood
test that can be provided in the physician’s office, has the
potential to improve screening participation.
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screening programs, from the invitation to screening
through to the completion of colonoscopy for patients
with positive tests.Additional file
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